Skip to main content

Table 2 Comparison of the median overall survival and median time to progression

From: Transcatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization alone to treat advanced hepatocellular carcinoma: a meta-analysis

Study

Median OS (month)

P

Median TTP (month)

P

Com

Con

Com

Con

Jiang 2010 [15]

–

–

–

6.2

3.1

< 0.001

Wei 2012 [16]

21.0

10.0

0.006

11.0

6.0

0.001

Ye 2013 [17]

14.8

8.2

0.023

10.3

5.8

0.035

Lencioni 2016 [13]

–

–

0.295

24.1 (wks)

23.7 (wks)

0.072

Kudo 2011 [26]

29.7

–

0.790

5.4

3.7

0.252

  1. Abbreviations: OS overall survival, TTP time to progression, Com combination group, Con control group, and - no description
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us